158808-63-0

Upstream product

• 51052-78-9 4-piperidinylacetic acid 
• 142355-82-6 methyl 4-piperidin-4-yl>butanoate 
• 142355-80-4 methyl 4-piperidin-4-yl>but-2-enoate 
• 142247-38-9 4-[1-(tert-butoxycarbonyl)piperidin-4-yl]butanoic acid 
• 157688-46-5 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid 
• 142355-83-7 4-(1-tert-butoxycarbonylpiperidin-4-yl)-butan-1-ol 
• 142374-19-4 tert-butyl 4-(formylmethyl)piperidine-1-carboxylate 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 501-53-1 benzyl chloroformate 
• 28356-58-3 pyridine-4-acetic acid 
• 142355-81-5 tert-butyl 4-(4-bromobutyl)piperidine-1-carboxylate 
• 158808-62-9 ethyl 2-(S)-methyl-2-amino>-3-(4-hydroxyphenyl)propionic acid ester 

Downstream Products

• 158808-64-1 4-{4-[4-((S)-2-Benzyloxycarbonylamino-2-carboxy-propyl)-phenoxy]-butyl}-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp

Inhibitors of platelet-fibrinogen binding offer an opportunity to interrupt the final, common pathway for platelet aggregation.Small molecule inhibitors of the platelet fibrinogen receptor GPIIb/IIIa were prepared and evaluated for their ability to prevent platelet aggregation.Compound 23m (L-700, 462/MK-383) inhibited in vitro platelet aggregation with an IC50 of 9 nM and demonstrated a selectivity of >24000-fold between platelet and human umbilical vein endothelial cell fibrinogen receptors.Dose-dependent inhibition of ex vivo platelet aggregation induced by ADP was achieved with iv infusions 0.1-10 μg/kg/min of 23m in anesthetized dogs, with 10 μg/kg/min completely inhibiting platelet aggregation during the entire 6 h infusion protocol.Platelet aggregatability returned rapidly after the termination of the 23m infusions.These features suggest that 23m may be useful in the treatment of arterial occlusive disorders.